EGFR and VEGFR as potential target for biological therapies in HCC cells

被引：48

作者：

Giannelli, Gianlulgi ^{[1
]}

Sgarra, Concetta ^{[1
]}

Porcelli, Letizia ^{[2
]}

Azzariti, Amalia ^{[2
]}

Antonaci, Salvatore ^{[1
]}

Paradiso, Angelo ^{[2
]}

机构：

[1] Univ Bari, Sez Med Interna, Policlin,Med Sch, Dipartimento Clin Med Immunol & Malattie Infett, I-70124 Bari, Italy

[2] Natl Canc Inst, Clin Expt Oncol Lab, Bari, Italy

来源：

CANCER LETTERS | 2008年 / 262卷 / 02期

关键词：

HCC; cell signalling vandetanib; gefitinib; EGFR; TK inhibitors; matrix metalloproteases;

D O I：

10.1016/j.canlet.2007.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Hepatocellular carcinoma (HCC) is a highly malignant cancer with poor prognosis. Inhibitors of EGFR and VEGFR for HCC treatment are currently under investigation. Gefitinib and vandetanib inhibit migration of HCC cells on Laminin-5 and Fibronectin, and invasion through matrigel. Both drugs inhibit p-EGFR after short time, while their efficacy on p-Erk1/2 and p-Akt is progressive and stable over time. PI3K/Akt and MEK/Erk1/2 inhibitors, inhibit migration and invasion as well as inducing de-phosphorylation of downstream effectors. Finally, both inhibitors, vandetanib and gefitinib down-regulated the secretion of matrix metalloproteases MMP-2 and MMP-9. All these biological effects seem to depend on the activity of gefitinib and vandetanib blocking activity towards p-EGFR mediated pathways. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：257 / 264

页数：8

共 22 条

[1]

Azzariti A, 2006, WORLD J GASTROENTERO, V12, P5140

[2]

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer [J].